

Influenza A virus research update from USDA National Animal Disease Center


Amy L. Vincent, DVM PhD
Research Veterinary Medical Officer
National Animal Disease Center
USDA-ARS

Pravina Kitikoon
Tavis Anderson
USDA-NADC Team

USDA-NVSL
USDA-NAHLN Laboratories
USDA-NSU



US Swine Producers and Veterinarians

USA H1 Tree



Tavis Anderson

USA H1 cartography




Virus Key

- Alpha
- Beta
- Gamma
- Swine pdm
- Human pdm
- Delta-1
- Delta-2
- Human H1

- 36 new viruses to generate swine anti-sera (x2)
 - 5 human strains
- 60 viruses tested against new antisera
- 29 viruses in previous H1 serum panel (x2)

Pravina Kitikoon and Nicola Lewis


USA H3 Tree



Kitikoon et al., J Gen Virol accepted

★ Expanding forward into 2013

USA N2 Tree



2012 human H3N2v
N2 among
predominantly δ1-
H1N2 2002-N2 genes

Nelson M I et al. J. Virol. 2012;86:8872-8878 Journal of Virology

Genotype patterns of contemporary reassorted H3N2 (rH3N2p) virus in U.S. swine

Genotype	PB2	PB1	PA	HA	NP	NA	M	NS	# of isolates
★ 1	Green	Blue	Green	A, E	Pink	2002	Light Green	Pink	23
2	Green	Blue	Green	A, E, F	Light Green	1998	Light Green	Pink	5*
3	Green	Blue	Light Green	B, D	Pink	2002	Light Green	Pink	2
4	Green	Blue	Green	F	Light Green	1998	Light Green	Light Green	14*
5	Green	Blue	Light Green	E	Light Green	2002	Light Green	Pink	1
6	Green	Blue	Light Green	D, F	Light Green	1998	Light Green	Light Green	5*
7	Light Green	Blue	Light Green	C, E	Light Green	2002	Light Green	Pink	3
8	Light Green	Blue	Light Green	D	Light Green	1998	Light Green	Light Green	1
9	Green	Light Green	Light Green	D	Light Green	2002	Light Green	Light Green	7
10	Light Green	Light Green	Light Green	C, D	Light Green	2002	Light Green	Light Green	3
TRIG	Green	Blue	Green	A	Pink	2002	Pink	Pink	55

■ North American H3 and N2 human lineage
 ■ TRIG avian lineage


■ Pandemic H1N1 origin

■ TRIG swine lineage

★ Viruses used in NADC pig studies

Are the genetic clusters impacting antigenic diversity?


H3 antibodies had inconsistent cross-reactivity among sub-clusters and with vaccines



Sera	I	IV					A			C	D		F		IV	I&IV	I
		TX/1998	MN/2006	IA/2007	MN/2009	IL/2009	PA/2010	IN/2011	NY/2011	IN/2012	IN/2011	IL/2011	IA/2011	IA/2011	TX/2011	Vaccine	Vaccine
Virus (cluster)																	
(I)																	
(IV)																	
(A)																	
(B)																	
(C)																	
(D)																	
(F)																	



USA H3 Cartography



Virus Key

- H3-c1
- H3-c3
- H3-c4
- H3-c4A
- H3-c4B
- H3-c4C
- H3-c4D
- H3-c4F
- Human H3

- 23 viruses to generate swine antisera (x2)
 - 8 human seasonal strains
 - 15 USA swine strains
- 34 viruses tested against antisera panel

Vaccines Tested in rH3N2 Studies

- Pfizer – FluSureXP (2 doses)
 - Cluster IV H3N2
- Novartis – PneumoStar SIV (1 dose)
 - Cluster I H3N2
- Intervet/Schering-Plough – MaxiVac Excell 5.0 (2 doses)
 - Cluster I and IV H3N2
- LAIV-1 – Δ NS1 (truncated NS1, no longer inhibits IFN- α)
 - Cluster I – TX98 with 1998 N2
- LAIV-1 – temperature-sensitive (polymerase mutations)
 - Cluster IV – OH04 with 2002 N2
- **Challenge with A/Sw/NY/A01104005/2011 or A/swine/Indiana/A00968373/2012**
 - **Genotype 1, H3 cluster A, N2 Cluster 2002**



rH3N2p Vaccine studies

- Study 1: Vaccine study with commercial vaccine with and without maternal antibody
 - **A/Sw/NY/A01104005/2011 rH3N2p-G1: mild challenge virus**
 - Commercial vaccine partially protective: reduced febrile response and replication, but did not prevent shedding
 - MDA interfered entirely with partial protection of vaccine
 - LAIV gave complete protection
 - WIV partial protection
- Study 2: 3 commercial WIV compared to 1998 LAIV and 2004 LAIV
 - **A/swine/Indiana/A00968373/2012: mild challenge virus**
 - 1 commercial Vx = “best” partial protection
 - Contained only 1 H3N2 virus (IV)
 - HI titer > 40 to IN/12 Ch virus
 - Still transmitted to naïve indirect contacts
 - 1 commercial vaccine = partial protection
 - Contained 2 H3N2 viruses (I & IV)
 - HI titer > 40 to IN/12 Ch virus
 - 1 commercial vaccine = minimal/no protection
 - Contained 1 H3N2 virus (I)
 - HI titer < 40 to IN/12 Ch virus
 - 1 LAIV = COMPLETE protection
 - IN delivery, 2004 H3N2 virus (IV)
 - HI titer < 40 to IN/12 Ch virus
 - No transmission to naïve contacts
 - 1 LAIV = partial protection
 - IN delivery, 1998 H3N2 virus (I)
 - HI titer < 40 to IN/12 Ch virus
 - Decreased lung viral burden
 - Decreased NS titers

NADC Team efforts

Summary of latest VAERD studies

- Cross-reacting IgG from WIV targets HA2 domain
- Mismatched HA subunit vaccine → **VAERD**
- NA matters too!
 - NA lineage mismatch, 1998 (A) vs. 2002 (B), with HA mismatch ($N2 \neq N2$) → **VAERD**
 - NA subtype mismatch with HA mismatch ($N2 \neq N1$) → **VAERD**
 - NA match with HA mismatch ($N2 = N2$) → No VAERD
 - NA mismatch with HA match → No VAERD



Acknowledgments

NADC

- Michelle Harland
- Gwen Nordholm
- Pravina Kitikoon
- Tavis Anderson
- Daniela Rajao
- Matt Sandbulte
- Katie Gibson

- Kelly Lager
- Crystal Loving
- Mark Kehrli
- Jason Huegel
- Jason Crabtree
- Darrell Bayles

- Phil Gauger
- Jamie Henningson
- Alessio Lorusso
- Doug Braucher
- Janice Zanella
- Eraldo Zanella
- Sabrina Swenson
- John Korslund
- Marie Gramer
- Nicola Lewis
- Daniel Perez
- Martha Nelson
- Richard Webby
- James Roth
- Ruben Donis
- Sasha Klimov
- Hana Golding
- Surender Khurana

- U.S. Producers and Swine Vets

- Funding:
USDA-ARS
USDA-APHIS
National Pork Board
CDC

